Updated review: Improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 4, Issue , 2011, Pages 29-37

  Richard III , John W ^a   Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Fixed dose combination; Metformin; Repaglinide; Type 2 diabetes

Indexed keywords

ACARBOSE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 80053615073     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S5094     Document Type: Review

References (44)

1. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. Apr 1998;15(4):290-6.
2. Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab. Apr 1999;84(4):1165-71.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. Aug 12 2000;321(7258):405-12.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. Jul 23 1998;339(4):229-34.
5. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai. Nov 2010;93 Suppl 6:S228-41.
6. Executive summary: Standards of medical care in diabetes, 2010. Diabetes Care. Jan 2010;33 Suppl 1:S4-10.
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. Jan 2009;32(1):193-203.
8. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. Mar 2002;24(3):460-7.
9. Hu S. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol. May 3 2002;442(1-2): 163-71.
10. Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. Jul 2004;112(7):395-400.
11. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. Dec 2004;53 Suppl 3:S156-64.
12. Smits P, Bijlstra PJ, Russel FG, Lutterman JA, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract. Jul 1996; 31 Suppl:S55-9.
13. Campbell IW. Nateglinide- current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. Oct 2005;59(10): 1218-28.
14. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. Jan 2003;59(1):43-9.
15. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD004654.
16. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract. Mar 1999; 43(3):155-66.
17. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. Jul 2003;26(7):2063-8.
18. Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract. Sep 2001;53(3):141-8.
19. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med. Oct 25 2004;164(19):2090-5.
20. Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther. Apr 1999;21(4):702-10.
21. Raskin P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes Obes Metab. Dec 2008;10(12): 1167-77.
22. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. Mar-Apr 1998;12(2):110-9.
23. Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. Sep 1999;16(9):755-61.
24. Wen YK. Impact of acute kidney injury on metformin-associated lactic acidosis. Int Urol Nephrol. Dec 2009;41(4):967-72.
25. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. Jan 1999;22(1):119-24.
26. Moses RG. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clin Ther. Mar 2008;30(3):552-4.
27. Reboussin DM, Goff DC Jr, Lipkin EW, et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med. Oct 2004;21(10):1082-9.
28. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J. Feb 2005;7(2):75-7.
29. Raskin P, Lewin A, Reinhardt R, Lyness W. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes Obes Metab. Oct 2009;11(10):947-52.
30. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones. Jul-Sep 2004;36(3):142-7.
31. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. Mar 2003;46(3):347-51.
32. Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract. Oct 2005;59(10):1131-6.
33. Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S136-9.
34. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. Jun 2004;20(6):883-9.
35. Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. Jul 2006;23(7):757-62.
36. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVEbeta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. Sep 2005;28(9):2093-9.
37. Garber AJ, Donovan DS J., Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. Aug 2003;88(8):3598-604.
38. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. Apr 5 2000;283(13):1695-702.
39. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. Sep 2000;50(1):49-56.
40. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. Dec 1998; 21(12):2050-5.
41. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. Dec 2006;29(12):2638-43.
42. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. Dec 2004;27(12):2874-80.
43. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. Aug 2007;120(8):713-9.
44. Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost- effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin. Aug 2004;20 Suppl 1:S41-51.